| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding | |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | Entrez:930 MIM:107265 HGNC:HGNC:1633 Ensembl:ENSG00000177455 AllianceGenome:HGNC:1633 | |
| Description | CD19 molecule | |||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding | |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | Entrez:933 MIM:107266 HGNC:HGNC:1643 Ensembl:ENSG00000012124 AllianceGenome:HGNC:1643 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | CD22 molecule | |||||
| GTO ID | GTC1077 |
| Trial ID | ChiCTR-OPN-16008526 |
| Disease | B-Cell Malignancy |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD22 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Recruiting |
| Title | An open-label, single-center and single-arm clinical study for sequential infusion of anti-CD22 and anti-CD19 CAR-T cells for patients with relapsed or refractory B-cell malignancies |
| Year | 2016 |
| Country | China |
| Company sponsor | Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| Cohort 1 | |||||||
|
|||||||